Estimating the cost-effectiveness of ribavirin and pegylated interferon alfa-2B for chronic hepatitis C.

被引：0
|
作者：
Wong, JB [1 ]
机构：
[1] Tufts New England Med Ctr, Boston, MA USA
来源：
HEPATOLOGY | 2000年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1062
引用
收藏
页码：425A / 425A
页数：1
相关论文
共 50 条
  • [41] Combination therapy with pegylated interferon ALFA-2B and ribavirin for patients with chronic hepatitis C and normal aminotransferase levels
    Kotano, Yoshiaki
    Ishigami, Mosatoshi
    Nakano, Isao
    Hayashi, Kozuhiko
    Honda, Takashi
    Goto, Hidemi
    HEPATOLOGY, 2007, 46 (04) : 397A - 397A
  • [42] Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alfa-2b and ribavirin for chronic hepatitis C
    Nishiofuku, Mariko
    Tsujimoto, Tatsuhiro
    Matsumura, Yoshinobu
    Toyohara, Masahisa
    Yoshiji, Hitoshi
    Yamao, Jun-ichi
    Fukui, Hiroshi
    Yoshikawa, Masahide
    INTERNAL MEDICINE, 2006, 45 (07) : 483 - 484
  • [43] Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C
    Michael R Kraus
    Arne Sch(a|¨)fer
    Herbert Csef
    Michael Scheurlen
    World Journal of Gastroenterology, 2005, (12) : 1769 - 1774
  • [44] Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C
    Kraus, Michael R.
    Schaefer, Arne
    Csef, Herbert
    Scheurlen, Michael
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (12) : 1769 - 1774
  • [45] PEGYLATED INTERFERON ALFA-2A VS PEGYLATED INTERFERON ALFA-2B, PLUS RIBAVIRIN, FOR CHRONIC HEPATITIS C GENOTYPE 4 PATIENTS: A RANDOMIZED CONTROLLED TRIAL
    Kamal, Sanaa
    Ghoraba, Dalia
    Nabegh, Leila
    Nasser, Imad
    Motaoe, Mona
    Sayed, Mohamed E.
    Gohary, Iman
    HEPATOLOGY, 2009, 50 (04) : 1025A - 1026A
  • [46] Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C
    Schaefer, A
    Scheurlen, M
    Csef, H
    Kraus, MR
    GASTROENTEROLOGY, 2004, 126 (04) : A695 - A695
  • [47] Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial
    Carrat, F
    Bani-Sadr, F
    Pol, S
    Rosenthal, E
    Lunel-Fabiani, F
    Benzekri, A
    Morand, P
    Goujard, C
    Pialoux, G
    Piroth, L
    Salmon-Céron, D
    Degott, C
    Cacoub, P
    Perronne, C
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23): : 2839 - 2848
  • [48] Pegylated interferon alfa-2b and fixed versus weight-based ribavirin dosing for treatment naive patients with chronic hepatitis C.
    Jacobson, I
    Brown, R
    Bernstein, D
    Bruno, C
    Spivey, J
    Lawitz, E
    Afdhal, N
    Flamm, S
    Freilich, B
    Pizov, O
    Russo, M
    Brass, C
    HEPATOLOGY, 2001, 34 (04) : 584A - 584A
  • [49] Evaluation of retinopathy in patients with hepatitis C on pegylated interferon alfa-2b and ribavirin: An interim analysis
    Sheinbaum, AJ
    Winn, JM
    Esrason, KT
    GASTROENTEROLOGY, 2003, 124 (04) : A776 - A776
  • [50] The cost-effectiveness of peginterferon alfa-2a (40kd) (PEGASYS) plus ribavirin (COPEGUS) vs. interferon alfa-2b plus ribavirin for chronic hepatitis C (CHC)
    Sullivan, SD
    Green, J
    Patel, KK
    Craxi, A
    Alberti, A
    Giuliani, G
    De Carli, C
    VALUE IN HEALTH, 2003, 6 (03) : 262 - 263
12345